Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This ...

Medically reviewed by Kelly Wood, MD The endocrine system is made of glands that produce hormones (chemical messengers), ...

Equities researchers at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 ...

Topline data were announced from a phase 3 trial evaluating eneboparatide in adults with chronic hypoparathyroidism.

The Work and Pensions Secretary has announced plans to tighten the eligibility criteria for Personal Independence Payment ...

AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...

AstraZeneca reports Phase 3 success for eneboparatide in hypoparathyroidism following $1.05B Amolyt Pharma acquisition. Drug ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...